$187 Million is the total value of Versant Venture Management, LLC's 10 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GRTS | Sell | Gritstone Oncology, Inc. | $45,796,000 | +5.9% | 3,561,150 | -11.1% | 24.49% | +36.7% |
| CRSP | CRISPR Therapeutics AG | $37,781,000 | -32.3% | 498,558 | 0.0% | 20.21% | -12.6% | |
| PASG | Passage Bio, Inc. | $31,495,000 | -36.2% | 4,959,769 | 0.0% | 16.84% | -17.6% | |
| ALGS | Aligos Therapeutics, Inc. | $27,543,000 | -23.5% | 2,320,381 | 0.0% | 14.73% | -1.1% | |
| AKRO | Akero Therapeutics, Inc. | $13,065,000 | -5.4% | 617,727 | 0.0% | 6.99% | +22.3% | |
| CRNX | Sell | Crinetics Pharmaceuticals, Inc. | $11,658,000 | -32.5% | 410,360 | -50.0% | 6.24% | -12.8% |
| ADVM | Adverum Biotechnologies, Inc. | $8,920,000 | -18.9% | 5,068,233 | 0.0% | 4.77% | +4.8% | |
| New | Minerva Surgical Inc. | $8,603,000 | – | 1,673,700 | +100.0% | 4.60% | – | |
| CBAY | CymaBay Therapeutics, Inc. | $1,838,000 | -7.4% | 543,753 | 0.0% | 0.98% | +19.6% | |
| CLVS | Clovis Oncology, Inc. | $276,000 | -39.2% | 101,855 | 0.0% | 0.15% | -21.3% | |
| FLXN | Exit | Flexion Therapeutics, Inc. | $0 | – | -1,000,000 | -100.0% | -2.53% | – |
| APRE | Exit | Aprea Therapeutics, Inc | $0 | – | -1,259,662 | -100.0% | -2.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-11 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.